Flagship Wealth Advisors LLC Buys Shares of 15,820 Pfizer Inc. (NYSE:PFE)

Flagship Wealth Advisors LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 15,820 shares of the biopharmaceutical company’s stock, valued at approximately $420,000.

Several other hedge funds have also bought and sold shares of PFE. Horizon Kinetics Asset Management LLC lifted its holdings in shares of Pfizer by 7.3% in the 4th quarter. Horizon Kinetics Asset Management LLC now owns 100,703 shares of the biopharmaceutical company’s stock worth $2,672,000 after acquiring an additional 6,888 shares during the last quarter. Curio Wealth LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $32,000. Pitti Group Wealth Management LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $375,000. Cibc World Markets Corp raised its holdings in Pfizer by 17.3% during the 4th quarter. Cibc World Markets Corp now owns 902,242 shares of the biopharmaceutical company’s stock valued at $23,936,000 after buying an additional 133,084 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV raised its holdings in Pfizer by 4.7% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 44,882 shares of the biopharmaceutical company’s stock valued at $1,191,000 after buying an additional 2,023 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

Pfizer stock opened at $25.74 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $145.85 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The firm has a 50 day simple moving average of $26.24 and a 200-day simple moving average of $27.12. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the business earned $0.10 EPS. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, March 12th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.